Biotechnology company BioTheryX Inc reported on Thursday the receipt of US Food and Drug Administration (FDA) clearance for the investigational new drug application (IND) for BTX-A51 for the treatment of patients with relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
In the third quarter of 2019, the company plans dosing of first patients with relapsed/refractory AML or high-risk MDS.
According to the company, BTX-A51 is a small molecule, oral multi-kinase inhibitor that appears to block a specific leukemic stem cell target (CK1-alpha) as well as super-enhancer targets (CDK7/CDK9) preventing transcription of key oncogenic genes.
Additionally, the company's pre-clinical assets include a library of novel small molecule, cereblon-binding targeted protein degraders, Protein Homeostatic Modulators (PHM). These IP-protected compounds are biologically active against a number of high value therapeutic targets in oncology, inflammation and other diseases.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Halia Therapeutics collaborates with Canary Speech
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007
Sanofi reports FDA approval for Dupixent in paediatric EoE treatment